XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.22.1

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2022 | Mar. 31, 2021
Disaggregation of Revenue [Line Items] |  |
Net sales | $ 4,178.2 | $ 4,400.1
Brands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 2,554.1 | 2,724.6
Complex GX and Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 390.8 | 328.9
Generics |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 1,233.3 | 1,346.6
Lipitor |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 440.1 | 464.6
Norvasc |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 207.8 | 227.7
Lyrica ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 171.7 | 187.8
Viagra ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 129.8 | 139.6
EpiPen® Auto-Injectors |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 88.8 | 103.7
Celebrex ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 85.2 | 89.0
Effexor ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 77.5 | 76.6
Zoloft ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 73.1 | 76.6
Creon ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 74.7 | 69.9
Xalabrands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 53.0 | 57.9
Amitiza ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 41.8 | 45.9
Xanax ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 40.0 | 45.1
Dymista ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 44.0 | 40.3
Yupelri ® |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 43.7 | 36.9
Developed Markets | Brands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 1,298.7 | 1,403.7
Developed Markets | Complex GX and Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 364.1 | 312.0
Developed Markets | Generics |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 813.3 | 855.9
Greater China | Brands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 569.7 | 590.9
Greater China | Complex GX and Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 0.0 | 0.0
Greater China | Generics |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 3.4 | 1.0
JANZ | Brands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 249.0 | 284.0
JANZ | Complex GX and Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 10.3 | 8.9
JANZ | Generics |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 164.5 | 189.0
Emerging Markets | Brands |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 436.7 | 446.0
Emerging Markets | Complex GX and Biosimilars |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 16.4 | 8.0
Emerging Markets | Generics |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 252.1 | 300.7
Operating Segment | Developed Markets |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 2,476.1 | 2,571.6
Operating Segment | Greater China |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 573.1 | 591.9
Operating Segment | JANZ |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | 423.8 | 481.9
Operating Segment | Emerging Markets |  |
Disaggregation of Revenue [Line Items] |  |
Net sales | $ 705.2 | $ 754.7

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_BrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_ComplexGXAndBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_GenericsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_LipitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_NorvascMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_LyricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_ViagraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_EpiPenAutoInjectorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_EffexorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_ZoloftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_CreonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_XalabrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_AmitizaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_XanaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_DymistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_YupelriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_DevelopedMarketsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_GreaterChinaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_JapanAustraliaAndNewZealandSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_EmergingMarketsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |